L’article Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium est apparu en premier sur Asceneuron.| Asceneuron
L’article Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron est apparu en premier sur Asceneuron.| Asceneuron
L’article Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth est apparu en premier sur Asceneuron.| Asceneuron
L’article The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA. est apparu en premier sur Asceneuron.| Asceneuron
L’article Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies est apparu en premier sur Asceneuron.| Asceneuron
L’article The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from March 28th to April 1st, in Gothenburg, Sweden. est apparu en premier sur Asceneuron.| Asceneuron
L’article Asceneuron’s CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland. est apparu en premier sur Asceneuron.| Asceneuron
L’article Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP) est apparu en premier sur Asceneuron.| Asceneuron
L’article Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on September 21st-22nd, 2022 in Basel. est apparu en premier sur Asceneuron.| Asceneuron
Asceneuron secures $100 million in a Series C financing to progress its lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease| Asceneuron